Phosphodiesterase inhibition and Ca2+ sensitization

Molecular and Cellular Biochemistry

Volumn 157, Issue 1-2, 1996, Pages 245-249

  Ravens, Ursula ^a   Himmel, Herbert M ^a   Flüss, Michael ^a   Davia, Kerry ^b   Harding, Sian E ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Action potential duration; Delayed rectifier K+ current; Human ventricular myocytes; Positive inotropic effect; Stereoselectivity; Thiadiazone derivatives

Indexed keywords

5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; 5 [1 (ALPHA ETHYLIMINO 3,4 DIMETHOXYBENZYL) 1,2,3,4 TETRAHYDRO 6 QUINOLINYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; AMRINONE; CALCIUM ION; CYCLIC AMP; ENOXIMONE; MILRINONE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PIMOBENDAN; PIROXIMONE; SULMAZOLE; THIADIAZINE DERIVATIVE; UNCLASSIFIED DRUG; CALCIUM;

ACTION POTENTIAL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CALCIUM CELL LEVEL; CLINICAL TRIAL; DRUG STRUCTURE; ENANTIOMER; ENZYME INHIBITION; GUINEA PIG; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILE FORCE; HEART RATE; HUMAN; INOTROPISM; ISOLATED HEART; NONHUMAN; NUCLEOTIDE METABOLISM; POTASSIUM CURRENT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; ANIMAL; CONGESTIVE HEART FAILURE; DRUG EFFECT; HEART; HEART CONTRACTION; HEART MUSCLE; IN VITRO STUDY; METABOLISM; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; REFERENCE VALUE; REVIEW; STEREOISOMERISM; SURVIVAL RATE;

CAVIA PORCELLUS; SUS SCROFA;

ANIMALS; ARRHYTHMIA; CALCIUM; CLINICAL TRIALS; CYCLIC AMP; GUINEA PIGS; HEART; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL CONTRACTION; MYOCARDIUM; PHOSPHODIESTERASE INHIBITORS; REFERENCE VALUES; STEREOISOMERISM; SURVIVAL RATE; THIADIAZINES;

EID: 0029666464     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00227906     Document Type: Article

References (21)

1. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, diBianco R, et al. for the PROMISE Study Research Group: Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325: 1468-1475, 1991
2. Feldman MD, Copelas L, Gwathmey JK, Philipps P, Warren SE, Schoen FJ, Grossman W, Morgan JP: Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 75: 331-339, 1987
3. Anderson JL, Askins JC, Gilbert EM, Menlove RL, Lutz JR: Occurrence of ventricular arrhythmias in patients receiving acute and chronic infusions of milrinone. Am Heart J 111: 466-474, 1986
4. Schmitz W, von der Leyen H, Meyer W, Neumann J, Scholz H: Phosphodiesterase inhibition and positive inotropic effects. J Cardiovasc Pharmacol 14 (Suppl 3): S11-S14, 1989
5. Schmitz W, Scholz H, Erdmann E: Effects of α- and β-adrenergic agonists, phosphodiesterase inhibitors and adenosine on isolated human heart muscle preparations. Trends Pharmacol Sci 8:447-450, 1987
6. Fischer TA, Erbel R, Treese N: Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure. Drugs 44: 928-945, 1992
7. Rüegg JC, Morano l: Calcium-sensitivity modulation of cardiac myofibrillar proteins. J Cardiovasc Pharmacol 14 (Suppl 3): S20-S23, 1989
8. max) in isolated contractile structures from mammalian heart muscle. Arzneim-Forsch/Drug Res 31 (I): 188-191, 1981
9. 2+ activation and the inotropic effect of pimobendan: comparison with milrinone. Circ Res 63: 911-922, 1988
10. Beier N, Harting J, Jonas R, Klockow M, Lues I, Haeusler G: The novel cardiotonic agent EMD 53 998 is a potent 'calcium sensitizer'. J Cardiovasc Pharmacol 18: 17-27, 1991
11. Solaro RJ, Gambassi G, Warshaw DM, Keller MR, Spurgeon HA, Beier N, Lakatta EG: Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments. Circ Res 73: 981-990, 1993
12. + current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 96: 195-215, 1990
13. K blocking drug, UK-68,798: potent in guinea-pig but no effect in rat myocardium. J Cardiovasc Pharmacol 16: 401-410, 1990
14. Yang T, Tande PM, Refsum H: Negative chronotropic effect of a novel class III antiarrhythmic drug, UK-68,798, devoid of β-blocking action in isolated guinea-pig atria. Br J Pharmacol 103: 1417-1420, 1991
15. Wallace M, Stupienski RF, Brookes LM, Selnick HG, Claremon DA, Lynch JJ: Cardiac electrophysiological and inotropic actions of new and potent methanesulfonanilide class III antiarrhythmic agents in anethetized dogs. J Cardiovasc Pharmacol 18: 687- , 1991
16. 2+ sensitization and phosphodiesterase III inhibitory effects in guinea pig myocardium. Circ Res 70: 1081-1090, 1992
17. Lues I, Beier N, Jonas R, Klockow M, Haeusler G: The two mechanisms of action of racemic cardiotonic EMD 53998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers. J Cardiovasc Pharmacol 21: 883-892, 1993
18. Ohler A, Ravens U: Effects of E-4031, almokalant and tedisamil on postrest action potential duration of human papillary muscles. J Pharmacol Exp Ther 270: 460-465, 1994
19. Harding SE, O Gara P, Jones SM, Brown LA, Vescovo G, Poole-Wilson PA: Species dependence of contraction velocity in single isolated cardiac myocytes. Cardioscience 1: 49-53, 1900
20. Davies CH, Davia K, Bennett JG, Pepper JR, Poole-Wilson PA, Harding SE: Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation 92: 2540-2549, 1995
21. Wettwer E, Grundke M, Ravens U: Differential effects of the new class lil antiarrhythmic agents almokalant, E-4031 and D-sotalol, and of quinidine, on delayed rectifier currents in guinea pig ventricular myocytes. Cardiovasc Res 26: 1145-1152, 1992